Pharsight

Combivent Respimat generic

Combivent Respimat is a spray, metered inhalation drug owned by Boehringer Ingelheim. It was first authorized for market use on 07 October, 2011. Its active ingredients are Albuterol Sulfate and Ipratropium Bromide. Up to date, Combivent Respimat has a total of 6 drug patents, none of which have expired.

When will Combivent Respimat generic be available?

The generic version of Combivent Respimat is due for release after 16 October, 2030. This date marks the expiry of the drug's last patent. Therefore, patients and healthcare providers can anticipate the availability of a more affordable generic option from this date.

Combivent Respimat uses

Combivent Respimat contains Albuterol Sulfate and Ipratropium Bromide as active ingredients. These components make it an effective treatment for chronic obstructive pulmonary disease (COPD). It works by relaxing the muscles around the airways and increasing air flow to the lungs.

Combivent Respimat patent expiration

Combivent Respimat has a total of six drug patents, all owned by Boehringer Ingelheim. These patents cover different technical aspects of the drug, from its delivery mechanism to its atomizing function. The last patent is set to expire on 16 October, 2030, after which Combivent Respimat generic may be made available. Below are the details of the patent:

EPO Oppostions filed on Combivent Respimat

Combivent Respimat dosage

Want to ask something?